Milestone Scientific (MLSS)
XASE:MLSS
Want to see MLSS full AI Analyst Report?
MLSS Stock Chart & Stats
$0.29
$0.17(16.41%)
At close: 4:00 PM EST
$0.29
$0.17(16.41%)
Day’s Range― - ―
52-Week Range$0.22 - $0.92
Previous CloseN/A
Volume1.27M
Average Volume (3M)172.66K
Market Cap
$30.96M
Enterprise Value$33.88M
Total Cash (Recent Filing)$1.19M
Total Debt (Recent Filing)$985.35K
Price to Earnings (P/E)―
Beta0.70
Next Earnings
Aug 18, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding88,449,410
10 Day Avg. Volume233,274
30 Day Avg. Volume172,658
Financial Highlights & Ratios
PEG Ratio-0.21
Price to Book (P/B)7.97
Price to Sales (P/S)2.50
P/FCF Ratio-7.64
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue3.80
Enterprise Value/Gross Profit5.41
Enterprise Value/Ebitda-7.81
Forecast
1Y Price Target
$1.00Price Target Upside244.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.04
Revenue Forecast (FY)$9.86M
Bulls Say, Bears Say
Bulls Say
High Gross MarginA sustained ~72% gross margin reflects structurally favorable unit economics for Milestone's products. High gross margins give the business a durable cushion to absorb fixed costs and fund scalable commercial investment; once sales scale, margins support lasting profitability.
Balance Sheet ReinforcementThe $2.15M private placement materially extends near-term runway and funds sales, inventory and marketing initiatives. This reduces immediate liquidity risk and enables execution on commercial expansion plans, making the company’s ability to pursue growth more durable over the next several quarters.
Structural Cost Reductions & Path To BreakevenManagement executed >30% opex cuts and improved operating loss ~58%, demonstrating tangible operating leverage and disciplined cost control. These structural savings materially lower the revenue threshold for breakeven and improve the probability of reaching cash-flow neutrality in early 2027.
Bears Say
Persistent Negative Cash FlowConsistent negative operating and free cash flow signals the business consumes cash rather than generates it, creating persistent funding needs. This structural cash burn increases refinancing and dilution risk and constrains the company's ability to invest in sustained commercial scaling without further capital.
Declining Trailing RevenueA nearly 25% TTM revenue decline undermines operating leverage and magnifies the difficulty of turning high gross margins into net profitability. Structural revenue weakness limits cash generation, pressures fixed-cost absorption, and lengthens the timeline to sustainable margins even with expense cuts.
CompuFlo Adoption & Reimbursement RiskMaterial growth expectations hinge on CompuFlo scaling from a very small base and securing favorable Medicare/MAC reimbursement. Regulatory and reimbursement timing are structural bottlenecks; delays or slower uptake would materially constrain nonlinear revenue growth and weaken the path to sustainable cash flow.
Milestone Scientific News
MLSS FAQ
What was Milestone Scientific’s price range in the past 12 months?
Milestone Scientific lowest stock price was $0.22 and its highest was $0.92 in the past 12 months.
What is Milestone Scientific’s market cap?
Milestone Scientific’s market cap is $30.96M.
When is Milestone Scientific’s upcoming earnings report date?
Milestone Scientific’s upcoming earnings report date is Aug 18, 2026 which is in 64 days.
How were Milestone Scientific’s earnings last quarter?
Milestone Scientific released its earnings results on May 14, 2026. The company reported -$0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.01.
Is Milestone Scientific overvalued?
According to Wall Street analysts Milestone Scientific’s price is currently Undervalued.
Does Milestone Scientific pay dividends?
Milestone Scientific does not currently pay dividends.
What is Milestone Scientific’s EPS estimate?
Milestone Scientific’s EPS estimate is -0.01.
How many shares outstanding does Milestone Scientific have?
Milestone Scientific has 88,449,410 shares outstanding.
What happened to Milestone Scientific’s price movement after its last earnings report?
Milestone Scientific reported an EPS of -$0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.286%.
Which hedge fund is a major shareholder of Milestone Scientific?
Currently, no hedge funds are holding shares in MLSS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Milestone Scientific Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.94%
12-Months-Change
Fundamentals
Return on Equity
-166.28%
Trailing 12-Months
Asset Growth
-12.38%
Trailing 12-Months
Company Description
Milestone Scientific
Milestone Scientific Inc. is dedicated to the innovation, refinement, and global distribution of advanced diagnostic and therapeutic injection technologies and devices. These solutions cater to the medical, dental, and cosmetic industries, with a presence in the United States, China, and other international markets. The company's operations are divided into two main segments: Dental and Medical. Within its Dental division, key products include CompuDent and the STA Single Tooth Anesthesia System, both instrumental for delivering local anesthetics across all dental procedures. For broader applications, the firm offers CompuFlo, a sophisticated computer-controlled system capable of delivering drugs, anesthetics, and other medicaments comfortably and precisely, as well as aspirating bodily fluids or prior injections. Complementing this, a disposable injection handpiece provides precise tactile control during administration. In the Medical segment, Milestone Scientific introduces the CompuFlo Epidural, a computer-guided anesthesia system designed for a variety of medical applications. Additionally, their CompuMed system is utilized in numerous specialized procedures, including plastic surgery, hair restoration, colorectal surgery, podiatry, dermatology, and orthopedics, among others. Headquartered in Livingston, New Jersey, Milestone Scientific Inc. was established in 1989.
MLSS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a cautiously positive outlook: management delivered meaningful expense reductions (>$1.3M, >30% YoY) and materially narrowed operating and net losses (both improved ~58%), while early traction in CompuFlo (medical revenue up >100% and roughly $108k in Q1), strong digital lead generation (152 leads), >50 reimbursement claims submitted, expansion of distributor and ambassador programs, and a $2.15M financing bolster the growth case. Key near-term risks remain—flat overall revenue for the quarter, a $200k shipping disruption, modest gross margin decline, CompuFlo's small absolute revenue base, and dependence on Medicare/MAC reimbursement timing and utilization to unlock nonlinear growth. Given that the positive operational improvements, financing, and early commercial traction outweigh the execution and reimbursement risks at this stage, the overall sentiment is constructive but cautious.View all MLSS earnings summariesMLSS Stock 12 Month Forecast
Average Price Target
$1.00
▲(244.83% Upside)
Technical Analysis
Retractable Technologies
―
Precision Optics Corporation
―
Nephros
―
Femasys
―
NexGel Inc
―
Ownership Overview
10.06% Insiders
2.97% Mutual Funds
0.39% Other Institutional Investors
84.25% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---